Tirzepatide
Dual GLP-1 / GIP receptor agonist with superior weight-loss data versus single agonists.
Recon & Dosing
Open the calculator for Tirzepatide vials.
- Category
- Metabolic / GLP-1
- Half-life
- ~5 days
- Typical vial
- 10 mg / 15 mg lyophilised
- Reported research dose
- 2.5–15 mg weekly in trial arms
Mechanism of action
Dual incretin agonism slows gastric emptying and enhances glucose-dependent insulin secretion.
Storage & handling
Lyophilised: 2–8 °C. Reconstituted: refrigerate, 28 days.
Run the reconstitution math →Research notes
- FDA-approved analogues exist under separate brand names.
- GI tolerance is dose-dependent.
Research use only. Figures above summarise published literature and community protocols for reference. Nothing here is a recommendation for human use.